Quan Lin
About Quan Lin
Quan Lin serves as the Senior Medical Director at Adaptimmune, where he oversees clinical studies and ensures compliance with protocols. With extensive experience in oncology and clinical research, he has held significant roles at institutions such as the University of Texas M.D. Anderson Cancer Center and Baylor College of Medicine.
Current Role at Adaptimmune
Quan Lin serves as the Senior Medical Director at Adaptimmune, a position he has held since 2019. In this role, he oversees the strategic direction and design of clinical development plans for various cancers. His responsibilities include ensuring compliance with study protocols and regulations, as well as representing Adaptimmune at high-level external joint steering or organizing committees. Lin's extensive experience in clinical trials contributes to the organization's focus on advancing immunotherapy and adoptive cell therapies.
Previous Experience in Clinical Research
Prior to his current role, Quan Lin worked at the University of Texas M.D. Anderson Cancer Center as a Clinical Studies Supervisor from 2011 to 2017. He also served as a Senior Clinical Research Coordinator at Baylor College of Medicine from 2007 to 2011. Earlier in his career, he was a Medical Advisor at AstraZeneca in the Great China Area for one year in 2001. His diverse background in clinical research spans multiple therapeutic areas, including oncology and dermatology.
Educational Background and Qualifications
Quan Lin earned his MD from Shanghai Second Medical University, where he studied from 1989 to 1994. He also completed a Master of Science in Laboratory Hematology at the same institution from 1994 to 1997. Lin furthered his education by obtaining a Certificate in Clinical Research Monitoring and Coordination from Michigan State University in 2007. He is certified by the Society of Clinical Research Associates (SoCRA), reflecting his commitment to maintaining high standards in clinical research.
Clinical Trials Expertise
Quan Lin has hands-on experience in all phases of clinical trials, from Phase I to IV. His work involves investigational drugs and medical devices across various therapeutic areas, including oncology, dermatology, endocrinology, pulmonology, gastroenterology, and organ transplantation. He establishes and approves scientific methods for clinical protocol design, implementation, and data collection systems. Lin actively contributes to critical documents such as protocols and regulatory submissions.
Contributions to Oncology Research
In his role, Quan Lin participates in the strategic direction and design of clinical development plans for multiple cancers, including gastroesophageal, melanoma, urothelial, head & neck, non-small cell lung cancer (NSCLC), ovarian cancer, synovial sarcoma, and myxoid/round cell liposarcoma. He maintains an up-to-date awareness of advances in immunotherapy oncology and adoptive cell therapies through scientific literature and relationships with key opinion leaders.